Please login to the form below
Biohaven Pharmaceuticals
This page shows the latest Biohaven Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Pfizer snaps up Biohaven’s migraine drug for $1.24bn
Neuroscience specialist Biohaven Pharmaceuticals has teamed up with Pfizer to commercialise its recently launched migraine drug Nurtec ODT (rimegepant) outside the United States. ... Moving forwards, Biohaven will continue to lead research and
Latest news
-
Biohaven gets FDA approval for migraine drug Nurtec ODT
Biohaven Pharma has become the second drugmaker to bring an oral CGRP inhibitor to the US market for acute migraine, after the US Food and Drug Administration (FDA) approved its Nurtec ... Biohaven says Nurtec ODT (rimegepant) – its first commercial
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
1. Rimegepant from BioHaven Pharmaceuticals is an antagonist of calcitonin gene-related peptide (CGRP), recently approved in the US for the acute treatment of migraine, with prevention trials also ongoing. ... Eli Lilly/Dong Pharmaceuticals’ 5-HT1f
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Humancomms for humancare?
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Genmab hires first chief operating officer
PMHub
IPG Health Medical Communications
We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...
Latest intelligence
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
